revenue $55.2M, net income -$164.1M. Nektar reports positive Phase 2b atopic dermatitis data, raises, but alopecia trial misses

Filed March 13, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 14, 2025 · ~2 min read

Key Changes

• high

  Phase 2b REZOLVE-AD trial met primary endpoint with statistical significance across all three dose arms in atopic dermatitis; maintenance data showed 71-83% of patients maintained EASI-75 responses at week 52 with less frequent dosing.

  Business: Phase 2b REZOLVE-AD results verify on EDGAR →
• high

  Phase 2b REZOLVE-AA trial in alopecia areata narrowly missed statistical significance on primary endpoint (p=0.186 and p=0.121), though both arms achieved significance when excluding four patients with eligibility violations.

  Business: Phase 2b REZOLVE-AA results verify on EDGAR →
• high

  Company raised approximately $656 million through three equity offerings in 2025-2026 (July 2025: $107M, Sept-Oct 2025: $73M, Feb 2026: $432M, plus $44M ATM), extending cash runway for Phase 3 development but diluting shareholders.

  MD&A: Capital raises verify on EDGAR →